MAPK3 and neuroblastoma: MEK1/2 or RAF-MEK1/2 pharmacological inhibitors displayed good inhibitory growth and survival effects, and decreased pERK1/2 levels, on NB cell lines with mutations in the RAS-ERK1/2 axis and high ERK1/2 activation under basal conditions [48,49,50,51].